CD8A and neoplasm: Despite contrasting therapeutic mechanisms between ICK and IL‐2‐Fc and small differences between mouse tumor models, in each instance ICK and IL‐2‐Fc treatments resulted in similar tumor growth inhibition due in large part to increased IFNγ+CD8+ T cells and/or decreased Tregs in the tumor.